Jazz Pharmaceuticals PLC

2026-09-11 20:02; UTC

UBS raised its price target on Jazz Pharmaceuticals to $337, maintaining a Buy rating amid confidence in growth prospects. Shares are trading higher today.

2026-09-08 20:03; UTC

Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.

2026-09-04 19:36; UTC

Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.

2026-09-03 21:21; UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.

2026-09-02 19:46; UTC

Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.

2026-09-01 19:54; UTC

Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.

2026-08-31 23:41; UTC

Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.

2026-08-28 20:02; UTC

Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.

2026-08-26 20:08; UTC

Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.

2026-08-25 20:07; UTC

Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.

2026-08-24 19:26; UTC

Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.

2026-08-22 00:02; UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.

2026-08-21 20:06; UTC

Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.

2026-08-20 19:56; UTC

Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.

2026-08-19 22:36; UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.

2026-08-18 20:03; UTC

Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.

2026-08-17 23:31; UTC

Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.

2026-08-12 19:46; UTC

Jazz Pharmaceuticals shares are higher after Q2 revenue rose 16% to $1.21 billion, exceeding expectations. The company raised its full-year guidance to $4.68 billion.

2026-08-11 22:46; UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading, diverging from broader market trends that closed lower amid rising crude oil prices.

2026-08-10 19:56; UTC

Jazz Pharmaceuticals PLC to acquire Actio Biosciences for $820 million, enhancing its rare epilepsy portfolio. Shares are higher despite earlier session pullback.

2026-08-07 19:36; UTC

Jazz Pharmaceuticals shares are higher today, reflecting broader market gains amid expectations the Federal Reserve may pause interest rate hikes.

2026-08-06 19:21; UTC

Jazz Pharmaceuticals PLC shares are lower today, despite earlier gains. Mixed economic signals contribute to cautious sentiment ahead of the non-farm payrolls report.

2026-08-05 19:36; UTC

Shares of Jazz Pharmaceuticals PLC are lower today, despite earlier gains. The company raised its full-year revenue guidance, driven by strong performance from Xywav.

2026-08-04 20:04; UTC

Jazz Pharmaceuticals PLC shares rise as analysts upgrade price targets, following strong Q2 results that beat revenue estimates and boosted 2026 sales guidance.

2026-08-03 23:02; UTC

Jazz Pharmaceuticals reported Q2 revenues of $1.208 billion, exceeding expectations. Shares advanced in after-market trading following the raised full-year guidance.

2026-07-31 23:21; UTC

Jazz Pharmaceuticals PLC shares are lower in after-market trading, pulled back from earlier session highs amid broader market declines, particularly in major tech stocks.

2026-07-30 19:59; UTC

Jazz Pharmaceuticals shares are higher, reflecting broader market recovery amid significant gains in the technology sector. The stock is near the upper end of its one-month range.

2026-07-29 18:26; UTC

Jazz Pharmaceuticals PLC is trading higher during Wednesday's session, with fluctuations within a routine range and positioned above its 20-day moving average.

2026-07-28 23:46; UTC

Jazz Pharmaceuticals PLC shares are higher in after-market trading, recovering from an early low and remaining above the 20-day moving average.

2026-07-27 19:37; UTC

Jazz Pharmaceuticals PLC is trading higher, recently reaching a new 52-week high amid increased investor interest and significant average volume exceeding $50 million.